UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Assessing oncologic benefit in clinical trials of immunotherapy agents

Annals of oncology, 2010-10, Vol.21 (10), p.1944-1951

2010

Volltextzugriff (PDF)

Clinical Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiation and Anti-PD-1 Therapy

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S57-S57

2015

Volltextzugriff (PDF)

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia

Gynecologic oncology, 2007-09, Vol.106 (3), p.558-566

2007

Volltextzugriff (PDF)

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

European journal of cancer (1990), 2015-09, Vol.51, p.S721-S721

2015

Volltextzugriff (PDF)

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

European journal of cancer (1990), 2015-09, Vol.51, p.S106-S107

2015

Volltextzugriff (PDF)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of oncology, 2019-04, Vol.30 (4), p.582-588

2019

Volltextzugriff (PDF)

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

European journal of cancer (1990), 2015-07, Vol.51, p.e24-e24

2015

Volltextzugriff (PDF)

Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

Anti CTLA4 and Predictive Biomarkers

Annals of oncology, 2012-09, Vol.23, p.ix46

Weber, J.S.

2012

Volltextzugriff (PDF)

71IN - Anti CTLA4 and Predictive Biomarkers

Annals of oncology, 2012-09, Vol.23, p.ix46-ix46

Weber, J.S.

2012

Volltextzugriff (PDF)

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

European journal of cancer (1990), 2014-11, Vol.50, p.48-49

2014

Volltextzugriff (PDF)

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Annals of oncology, 2013-08, Vol.24 (8), p.2174-2180

2013

Volltextzugriff (PDF)

The mutagenic action of N-ethyl-N-nitrosourea in the mouse

Mammalian genome, 2000-07, Vol.11 (7), p.478-483

2000

Volltextzugriff (PDF)

Effect of Ti/Si and Ti/TiN/Si interlayers on the structure, properties, and tribological behavior of an a-C film deposited onto a C17200 copper-beryllium alloy

Surface & coatings technology, 2022-07, Vol.441, p.128561, Article 128561

2022

Volltextzugriff (PDF)

1077MO Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K

Annals of oncology, 2024-09, Vol.35, p.S713-S714

2024

Volltextzugriff (PDF)

1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

Annals of oncology, 2024-09, Vol.35, p.S727-S728

2024

Volltextzugriff (PDF)

1314PD - Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

Annals of oncology, 2019-10, Vol.30, p.v535-v535

2019

Volltextzugriff (PDF)

Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

Annals of oncology, 2019-10, Vol.30, p.v535

2019

Volltextzugriff (PDF)

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

Annals of oncology, 2023-10, Vol.34, p.S1288-S1289

2023

Volltextzugriff (PDF)

1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma

Annals of oncology, 2023-10, Vol.34, p.S657-S658

2023

Volltextzugriff (PDF)

1034TiP ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma

Annals of oncology, 2021-09, Vol.32, p.S865-S866

2021

Volltextzugriff (PDF)

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

Annals of oncology, 2021-09, Vol.32, p.S869-S869

2021

Volltextzugriff (PDF)

844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Annals of oncology, 2022-09, Vol.33, p.S935-S936

2022

Volltextzugriff (PDF)

788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)

Annals of oncology, 2022-09, Vol.33, p.S904

2022

Volltextzugriff (PDF)

1364P - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumours

Annals of oncology, 2019-10, Vol.30, p.v556-v556

2019

Volltextzugriff (PDF)

1 – 25 von 258

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(225)
Mit Volltextzugriff
(244)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(110)
Physics
(53)
Life Sciences & Biomedicine
(52)
Physical Sciences
(49)
Technology
(32)
Animals
(26)
Biological And Medical Sciences
(23)
Humans
(21)
Materials Science
(19)
Fundamental And Applied Biological Sciences. Psychology
(17)
Chemistry
(13)
Female
(12)
Agriculture
(11)
Exact Sciences And Technology
(11)
Hematology, Oncology And Palliative Medicine
(11)
Materials Science, Multidisciplinary
(11)
Physics, Applied
(11)
Chemistry, Physical
(10)
Food Science & Technology
(10)
Oncology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Assessing oncologic benefit in clinical trials of immunotherapy agents

Clinical Outcomes of Melanoma Brain Metastases Treated With Stereotactic Radiation and Anti-PD-1 Therapy

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules

Anti CTLA4 and Predictive Biomarkers

71IN - Anti CTLA4 and Predictive Biomarkers

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

The mutagenic action of N-ethyl-N-nitrosourea in the mouse

Effect of Ti/Si and Ti/TiN/Si interlayers on the structure, properties, and tribological behavior of an a-C film deposited onto a C17200 copper-beryllium alloy

1077MO Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K

1098P Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

1314PD - Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

Cell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response

1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma

1034TiP ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma

1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)

1364P - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumours

Aktive Filter

Suchergebnisse filtern